IP Library Granted Patent US 11,584,932
Granted Patent B2
US 11,584,932 · App. 16/176,137 · Granted Feb 21, 2023

5-halouracil-modified microRNAs and their use in the treatment of cancer

Inventors: Jingfang Ju (East Setauket, NY); Andrew Fesler (Sound Beach, NY)
Assignee: The Research Foundation for The State University of New York
C12N15/1135A61K31/712A61K45/06A61K48/00A61P35/00C07H21/02C12N2310/14C12N2310/141C12N2310/335C12N2310/3533
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,584,932
App. No.
16/176,137
Granted
Feb 21, 2023
Kind
B2
Abstract

The present disclosure provides nucleic acid compositions that incorporate one or more halouracil molecules. More specifically, the present disclosure reveals that the replacement of uracil nucleotides within a microRNA nucleotide sequence with a 5-halouracil increases the ability of the micro-RNA to inhibit cancer progression and tumorigenesis. As such, the present disclosure provides various nucleic acid (e.g., microRNA) compositions having 5-halouracil molecules incorporated in their nucleic acid sequences and methods for using the same. The present disclosure further provides pharmaceutical compositions comprising the modified nucleic acid compositions, and methods for treating cancers using the same.

Claims (7)

1. A double-stranded nucleic acid comprising a modified microRNA nucleotide sequence that comprises uracil nucleic acids, wherein all the uracil nucleic acids including the seed region of the modified microRNA nucleotide sequence, which are complementary to a B-cell lymphoma 2 (BCL2) nucleotide sequence, are 5-fluorouracils, to combine the potency of microRNA nucleotide sequence and 5-fluorouracils, and wherein the modified microRNA nucleotide sequence binds to the B-cell lymphoma 2 (BCL2) nucleotide sequence that is complementary to the miR-129 microRNA nucleotide sequence set forth in SEQ ID NO: 1 or the miR-15a microRNA nucleotide sequence set forth in SEQ ID NO: 2.

2. A pharmaceutical composition comprising at least one double-stranded nucleic acid of claim 1 .

3. The pharmaceutical composition of claim 2 , wherein said modified microRNA nucleotide sequence comprises the miR-15a nucleotide sequence.

4. The pharmaceutical composition of claim 2 , wherein said modified microRNA nucleotide sequence comprises the miR-129 nucleotide sequence.

5. The double-stranded nucleic acid of claim 1 , wherein the modified microRNA nucleotide sequence comprises the miR-129 nucleotide sequence.

6. The double-stranded nucleic acid of claim 1 , wherein modified microRNA nucleotide sequence comprises the miR-15a nucleotide sequence.

7. The double-stranded nucleic acid of claim 6 , wherein the modified microRNA nucleotide sequence is UAGCAGCACAU F AAU F GGU F U F U F GU F G [SEQ ID NO. 7].

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 31, 2018
From: JU, JINGFANG; FESLER, ANDREW
To: THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK
Reel/Frame 047368/0945 →
Continuity (5)
Continuation In Part PCTUS2017059011 · Oct 30, 2017
Provisional Application 62464491 · Feb 28, 2017
Provisional Application 62422298 · Nov 15, 2016
Provisional Application 62415740 · Nov 1, 2016
Related Publication 20190062754A1 · Feb 28, 2019